Alexandros Zampetakis

Prof. Alexandros Zampetakis

Neurology department, University of Crete, Réthymno, Kríti, Greece

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Brain Imaging and Behavior
Verified
Journal Article
Closed access
PDF file
EPEfrosini Papadaki
Efrosini Papadaki
EKEleftherios Kavroulakis
Eleftherios Kavroulakis
KMKatina Manolitsi
Katina Manolitsi
DMDimitrios Makrakis
Dimitrios Makrakis
EPEmmanouil Papastefanakis
Emmanouil Papastefanakis
PSPanagiotis Simos
Panagiotis Simos

27 February 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
maria bastamaria basta
maria basta
ESEleni Skourti
Eleni Skourti
Christina AlexopoulouChristina Alexopoulou
Christina Alexopoulou
AZAlexandros Zampetakis
Alexandros Zampetakis
AGAndronikos Markelos Ganiaris
Andronikos Markelos Ganiaris
AVAlexandros N. Vgontzas
Alexandros N. Vgontzas
Identifying modifiable factors that may predict long-term cognitive decline in the elderly with adequate daily functionality is critical. Such factors may include poor sleep quality and quantity, sleep-related breathing disorders, inflammatory cytokines and stress hormones, as well as mental health problems. This work reports the methodology and descriptive characteristics of a long-term, multidisciplinary study on modifiable risk factors for cognitive status progression, focusing on the 7-year follow-up. Participants were recruited from a large community-dwelling cohort residing in Crete, Greece (CAC; Cretan Aging Cohort). Baseline assessments were conducted in 2013–2014 (Phase I and II, circa 6-month time interval) and follow-up in 2020–2022 (Phase III). In total, 151 individuals completed the Phase III evaluation. Of those, 71 were cognitively non-impaired (CNI group) in Phase II and 80 had been diagnosed with mild cognitive impairment (MCI). In addition to sociodemographic, lifestyle, medical, neuropsychological, and neuropsychiatric data, objective sleep was assessed based on actigraphy (Phase II and III) and home polysomnography (Phase III), while inflammation markers and stress hormones were measured in both phases. Despite the homogeneity of the sample in most sociodemographic indices, MCI persons were significantly older (mean age = 75.03 years, SD = 6.34) and genetically predisposed for cognitive deterioration (APOE ε4 allele carriership). Also, at follow-up, we detected a significant increase in self-reported anxiety symptoms along with a substantial rise in psychotropic medication use and incidence of major medical morbidities. The longitudinal design of the CAC study may provide significant data on possible modifiable factors in the course of cognitive progression in the community-dwelling elderly.